Vermont’s medical cannabis program is undergoing an extensive review, mandated by Act 65, with aims to address critical structural issues such as program enrollment decline, and constraints on product availability for medicinal use. The review is led by James Pepper, the Chairman of the Cannabis Control Board, and includes a diverse range of stakeholders, focusing particularly on treatment protocols and education for new medical cannabis patients. According to reporting from the Brattleboro Reformer, the agency’s report will include feedback from members of the cannabis industry, patients, caregivers, and the University of Vermont.
The results of the review are projected to be released by January 15th. There could be significant modifications to the program including a reduction in administrative burdens, updates to caregiver plant limits, and the elimination of certain prerequisites that currently exist for PTSD patients to qualify. These revisions all aim to make the program more accessible and user-friendly for qualifying patients. Additionally, Vermont aspires to bolster consumer protection by focusing on stringent testing protocols and enhancing training standards for employees to assure the safety and quality of medical cannabis products are maintained.
Find the full story from the Brattleboro Reformer on their website here: https://www.reformer.com/cannabis/vermont-reviews-its-medical-cannabis-program/article_effffa04-57e2-11ee-9303-cf4681efb109.html
